Current dividend yield | 2.71 % |
Dividendenrendite 5 Jahre | 4.88 % |
Dividend Yield 10Y | 8.15 % |
Payout 3Y | 2.54 % |
The Trinity Biotech Plc Sponsored ADR Class A stock dividend is paid once a year. In order to receive a dividend, you should generally own the Trinity Biotech Plc Sponsored ADR Class A stock before the ex-dividend date. The Dividend Calendar shows that the ex-day date was last at . The dividend from Trinity Biotech Plc Sponsored ADR Class A was paid in July.
Year | Dividend | Ex-day & Payday |
Frequency | |
---|---|---|---|---|
Fiscal Year | Dividend per Share | Ex-Day | Payday | Payment frequency |
2015 |
$1.1
$1.1
|
Jun 05 2015
Jun 05 2015
Jul 01 2015
Jun 05 15
Jul 01 15 |
Jul 01 2015 |
annual
yearly
|
2014 |
$1.1
$1.1
|
Jun 06 2014
Jun 06 2014
Jul 01 2014
Jun 06 14
Jul 01 14 |
Jul 01 2014 |
-
-
|
2013 |
$1
$1
|
Jun 06 2013
Jun 06 2013
Jul 01 2013
Jun 06 13
Jul 01 13 |
Jul 01 2013 |
annual
yearly
|
2012 |
$0.75
$0.75
|
Jun 06 2012
Jun 06 2012
Jun 22 2012
Jun 06 12
Jun 22 12 |
Jun 22 2012 |
-
-
|
2011 |
$0.5
$0.5
|
Jun 07 2011
Jun 07 2011
Jun 23 2011
Jun 07 11
Jun 23 11 |
Jun 23 2011 |
semi annual
semi-annual
|
Trinity Biotech Plc Sponsored ADR Class A paid a Dividend of $0.00 Per Share in the financial year 2023. With a stock price of $0.80 at Dec 27 2024, the current dividend yield is 0.00% (calculation: $0.00 / $0.80 = 0.00%). No special dividend was paid.
The average Trinity Biotech Plc Sponsored ADR Class A dividend yield over the last 5 years is 0.00% and the average over the last 10 years is 0.65%.
The payout ratio of Trinity Biotech Plc Sponsored ADR Class A in relation to the last financial year is 0.00%. The payout ratio smoothed over 3 years is 0.00%. The calculation is based on the sum of all dividend payments divided by the cumulative earnings per share(EPS).
Metric | Trinity Biotech Plc Sponsored ADR Class A |
---|---|
Current dividend yield | 0.00% |
Dividend Yield 5Y | 0.00% |
Dividend Yield 10Y | 0.65% |
Payout 1Y | 0.00% |
Payout 3Y | 0.00% |
Trinity Biotech Plc Sponsored ADR Class A has been paying a dividend for 0 years and has not lowered the dividend for 0 years (dividend continuity). As a result, the dividend was not increased recently.
The average for the last 10 years is -100.00%.
Metric | Trinity Biotech Plc Sponsored ADR Class A |
---|---|
Increased | 0 Years |
Continuity | 0 Years |
Paid | 0 Years |
Growth 10Y | -100.00% |
Trinity Biotech Plc Sponsored ADR Class A has been paying a dividend for 0 years and has not lowered the dividend for 0 years (dividend continuity). As a result, the dividend was not increased recently.
The average for the last 10 years is -100.00%.
On the stock exchange, the Trinity Biotech Plc Sponsored ADR Class A stock (ISIN: US8964383066) is not traded as a top scorer in December 2024 according to the dividend strategy.
The stock price of Trinity Biotech Plc Sponsored ADR Class A -62.62% has fallen since the beginning of the year 2024. However, the return generated in the past says nothing about the future return. You can find the Trinity Biotech Plc Sponsored ADR Class A stock price in real time at the top of the page.
Trinity Biotech Plc Sponsored ADR Class A (symbol: TRIB) is valued at a Price / Earnings Ratio (P/E ratio) of -0.35 and a price/sales ratio (P/S ratio) of 0.15 valued. Based on analyst estimates, the Trinity Biotech Plc Sponsored ADR Class A stock forecast 2024 of the current financial year corresponds to a valuation of 0.15 according to P/S.
Metric | Trinity Biotech Plc Sponsored ADR Class A |
---|---|
Dividend Score | ??/15 |
Performance 2024 |
62.62%
|
P/E TTM | -0.35 |
P/S TTM | 0.15 |
P/S forward | 0.15 |
Trinity Biotech Plc Sponsored ADR Class A (symbol: TRIB) is valued at a Price / Earnings Ratio (P/E ratio) of -0.35 and a price/sales ratio (P/S ratio) of 0.15 valued. Based on analyst estimates, the Trinity Biotech Plc Sponsored ADR Class A stock forecast 2024 of the current financial year corresponds to a valuation of 0.15 according to P/S.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.